Glickman Urological & Kidney Institute Outcomes
Urology - Prostate
Prostate Intro
The Center for Urologic Oncology’s prostate cancer program offers innovative, leading edge care for prostate cancer patients, including all treatment modalities for localized and locally advanced disease. Treatment options include open and robotic prostatectomy, cryotherapy, and, in conjunction with the Department of Radiation Oncology, I-125 brachytherapy and Calypso®-based, image-guided, intensity-modulated external beam radiotherapy.
In the outcomes graphs that follow, patient groups are defined as:ᵃ
- Low risk: Gleason score ≤ 6, clinical stage ≤ T2a, and prostate-specific antigen (PSA) level < 10 ng/mL
- Intermediate risk: All other criteria not fitting the definition of low risk or high risk
- High risk: Gleason score ≥ 8 and/or clinical stage > T2b and/or PSA > 20 ng/mL
Biochemical Relapse Free Survival of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N = 2400)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 510) | 96.0% (350) | 85.7% (145) | 66.6% (26) |
| Low-Dose-Rate Brachytherapy (N = 1890) | 95.4% (902) | 86% (211) | 69.0% (30) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Biochemical Relapse Free Survival of Patients With Favorable Intermediate-Risk Prostate Cancer by Treatment Typeᵃ (N = 1415)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 243) | 91.1% (144) | 77.3% (67) | 57.8% (4) |
| Low-Dose-Rate Brachytherapy (N = 1172) | 94.1% (390) | 84.1% (55) | 64.3% (11) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Biochemical Relapse Free Survival of Patients With Unfavorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N = 1709)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 423) | 79.7% (209) | 62.0% (81) | 42.1% (16) |
| Low-Dose-Rate Brachytherapy (N = 1283) | 81.9% (346) | 56.0% (49) | 41.5% (6) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Biochemical Relapse Free Survival of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N = 1066)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 646) | 71.6% (293) | 47.8% (98) | 36.5% (13) |
| Low-Dose-Rate Brachytherapy (N = 420) | 64.0% (115) | 34.3% (12) | NA (0) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N= 2400)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 510) | 0.87% (409) | 1.87% (225) | 5.82% (65) |
| Low-Dose-Rate Brachytherapy (N = 1890) | 0.23% (1047) | 2.02% (317) | 3.87% (73) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With Favorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N= 1415)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 243) | 1.00% (171) | 2.67% (107) | 8.18% (16) |
| Low-Dose-Rate Brachytherapy (N = 1172) | 0.19% (459) | 1.39% (92) | 2.92% (20) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With Unfavorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N= 1709)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 423) | 3.36% (295) | 7.09% (165) | 10.45% (49) |
| Low-Dose-Rate Brachytherapy (N = 1283) | 0.55% (480) | 2.80% (121) | 7.56% (18) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N= 1066)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 646) | 5.50% (447) | 13.76% (250) | 19.78% (68) |
| Low-Dose-Rate Brachytherapy (N = 420) | 3.86% (204) | 10.10% (46) | 13.10% (16) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
